• Sunitinib Resistance in RCC: Mechanistic Insights and Future

  2026-06-16

  This thought-leadership article explores the evolving landscape of sunitinib resistance in renal cell carcinoma (RCC), blending a mechanistic understanding of multi-targeted receptor tyrosine kinase (RTK) inhibition with actionable guidance for translational researchers. By integrating recent discoveries on ferroptosis, combination strategies, and robust experimental protocols, it offers a forward-looking roadmap for overcoming therapeutic barriers and maximizing research impact.

• HotStart™ 2X Green qPCR Master Mix: Precision for Biomarker

  2026-06-15

  Discover how HotStart 2X Green qPCR Master Mix advances SYBR Green qPCR for biomarker validation in oncology. Explore protocol depth, assay optimization, and novel insights for translational biomarker research.

• Protocols for Avian Auditory Hair Cell Ablation and Regenera

  2026-06-15

  This reference paper establishes a reproducible protocol for targeted elimination of avian auditory hair cells, followed by multiplexed mRNA detection, immunohistochemistry, and S-phase labeling to analyze regeneration. The methodology enables high-resolution dissection of gene expression and proliferative responses in the regenerating inner ear, advancing mechanistic studies of sensory recovery.

• Dual-Action Kinase Inhibitors Accelerate p38α Dephosphorylat

  2026-06-14

  The reference study reveals that certain kinase inhibitors, including those relevant to Imatinib hydrochloride (STI571 hydrochloride), not only inhibit kinase activity but also enhance dephosphorylation of p38α MAP kinase by stabilizing a conformation favorable for phosphatase activity. This dual-action mechanism deepens our understanding of kinase-phosphatase dynamics and suggests new strategies for developing more selective and potent kinase inhibitors in cancer research.

• O-GlcNAcylation Drives Wnt-Induced Glycolysis in Bone Format

  2026-06-13

  This study uncovers how O-GlcNAcylation serves as a key mediator of Wnt3a-induced bone formation by rewiring aerobic glycolysis in osteoblasts. The findings reveal a dual mechanism for O-GlcNAcylation activation and identify its indispensability for osteogenesis, offering new insights for metabolic and signaling pathway research in bone biology.

• Nebivolol Hydrochloride: Selectivity, Assay Design, and mTOR

  2026-06-12

  Explore Nebivolol hydrochloride as a highly selective β1-adrenoceptor antagonist for cardiovascular and signaling research. This article reveals new experimental considerations, recent mTOR pathway findings, and advanced assay design strategies beyond typical applications.

• Masitinib (AB1010): Technical Use in KIT/PDGFR Inhibition Wo

  2026-06-12

  Masitinib (AB1010) addresses the need for precise inhibition of the KIT, PDGFRα, and PDGFRβ tyrosine kinases in cancer biology, mastocytosis, and inflammation model systems. It is best suited for DMSO-based workflows where selective kinase targeting is required and should not be used in protocols that depend on broad-spectrum inhibition or require aqueous/ethanol solubility.

• Imatinib Hydrochloride: Optimized Workflows for Kinase Inhib

  2026-06-11

  Imatinib hydrochloride enables precise, multi-target kinase inhibition for advanced cancer research, from CML to GISTs. This article details experimental best practices, protocol optimization, and troubleshooting tips, leveraging both emerging mechanistic insights and APExBIO’s high-purity reagent standards.

• Epigenetic Modulation Shapes Immune Signatures in Melanoma

  2026-06-11

  Anichini et al. (2022) systematically profiled immune-related gene signatures induced by different classes of epigenetic regulators in melanoma, finding that the DNMT inhibitor guadecitabine uniquely enhances immune activation programs with clinical relevance. Their findings clarify the molecular rationale for combining specific epigenetic drugs with immunotherapy, offering new directions for translational cancer research.

• Intravesical p21 mRNA-LNP Therapy for Bladder Cancer: Eviden

  2026-06-10

  A recent open-access study demonstrates that intravesical delivery of p21 mRNA–loaded lipid nanoparticles (LNPs) can restore tumor suppressor function and suppress tumor growth in non–muscle-invasive bladder cancer. This approach leverages localized mRNA therapy to overcome limitations of standard treatments, with strong mechanistic and preclinical support for clinical translation.

• Drug-Sensitized Yeast as a Sensitive Platform for mTOR Inhib

  2026-06-10

  The referenced study establishes a drug-sensitized yeast system to dramatically enhance the detection sensitivity for TOR/mTOR inhibitors, enabling identification of both established and novel compounds with TOR pathway activity. This approach offers a rapid, cost-effective means to screen for geroprotective or anti-cancer agents targeting mTOR, while also clarifying compound specificity for researchers.

• Tofacitinib Citrate: Applied Strategies in Immune Regulation

  2026-06-09

  Tofacitinib citrate (CP-690550 citrate) empowers researchers to dissect JAK-STAT pathway dynamics and endothelial inflammation with exceptional selectivity. Discover protocol-driven insights, troubleshooting strategies, and how recent vascular studies guide experimental design for immune and inflammatory models.

• Afatinib (BIBW 2992) in Advanced Gastric Cancer Assembloid M

  2026-06-09

  Harnessing Afatinib’s irreversible ErbB kinase inhibition, researchers can dissect drug response and resistance in physiologically relevant gastric cancer assembloids. This article provides actionable protocol enhancements, troubleshooting, and workflow tips to maximize the translational value of Afatinib (BIBW 2992) in next-generation cancer biology research.

• LGK-974 (Porcupine Inhibitor): Reliable Solutions for Wnt Pa

  2026-06-08

  This article provides practical, evidence-based guidance for biomedical researchers seeking robust and reproducible Wnt pathway inhibition using LGK-974 (Porcupine Inhibitor), SKU B2307. Drawing on validated protocols and recent literature, we address key challenges in experimental design, data interpretation, and product selection—demonstrating why APExBIO’s LGK-974 is a trusted resource for sensitive cell-based assays and Wnt-driven cancer models.

• Patient-Derived Gastric Cancer Assembloids Reveal Stromal Mo

  2026-06-08

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids and stromal cell subpopulations, enabling unprecedented investigation into the tumor microenvironment. The model enhances physiological relevance for preclinical research, reveals stromal-driven drug resistance, and supports more predictive, personalized therapy strategies.

15291 records 7/1020 page Previous Next First page 上5页 678910 下5页 Last page